2 0 1 8
The world’s first ingestible supplement to help manage eczema and dry skin
According to the ‘Global Burden of Disease’ study, eczema is the leading contributor of all skinrelated disabilities, affecting up to 2-4% of the global population. The recent encouragement of frequent handwashing, wearing of masks and prolonged use of personal protective equipment has further increased the frequency and severity of eczema across the general population. A recent study showed that hand eczema tripled in young children during Spring 2020, when mandatory hand hygiene regimens were in force. Dr Neil Gibbs FRSB, renowned skin biologist, has worked in the dermatology sector for over 40 years. He is the inventor and entrepreneur behind pellamex, the world’s first skincare supplement formulated for sensitive and eczemaprone skin, designed to feed the skin barrier protein, filaggrin. The journey to develop pellamex began after a landmark paper was published that identified filaggrin as a significant factor in causes of eczema. Dr Gibbs then researched and clinically validated the ‘filaggrin feeding’ technology at the University of Manchester Dermatology Centre and launched pellamex.
The first of its kind in the global market, pellamex offers an alternative way for patients to take back control of their skin. With a unique patented formula, combining a high purity amino acid with other key EFSA-approved skin nutrients such as zinc, biotin, vitamins B2, B3 and E. It works with the skin’s biology to strengthen and restore the skin barrier. The active ingredient, l-histidine, is a natural amino acid that acts as a key building block for filaggrin, which eventually gets broken down into natural moisturising factor (NMF) in the epidermis, ultimately hydrating the skin from the inside.
Filaggrin is important in maintaining a normal healthy skin barrier, which we all need in an increasingly polluted world, but especially those with dry, sensitive and eczema prone skin. When filaggrin fails, the skin barrier is disrupted and this can lead to dry skin, irritation and atopic dermatitis. Research has shown that the pellamex active ingredient helps skin cells to make filaggrin and, unlike creams and lotions,
reaches the entire skin area, helping to block the entry of irritants and allergens and retain essential hydration. Pellamex’s technology has been assessed in a randomised, double blind placebocontrolled study in both adults and children with atopic dermatitis, who saw a 40% and 49% improvement in their skin respectively over the study period. “This is the largest effect of any treatment affecting the skin barrier in atopic dermatitis that I have seen in a clinical trial. Seriously impressive effects.”
A commenting on the adult study by: Professor Mike Cork Professor of Dermatology University of Sheffield
The daily 25ml dose comes in a portable sachet and can be consumed straight away or dissolved into water for a refreshing drink. A one-month supply (30 sachets) costs £49.99 and is available from www. pellamex.com or through subscription saving 15% per box (minimum six months).
www.pellamex.com
53
